Therapeutic effects of adenovirus‑mediated CD and NIS expression combined with Na131I/5‑FC on human thyroid cancer

Yuan,Meng‑Hui; Wei,Long‑Xiao; Zhou,Run‑Suo; Xu,Hai‑Feng; Wang,Jun‑Yan; Bai,Qian‑Rong

doi:10.3892/ol.2017.7175

Therapeutic effects of adenovirus‑mediated CD and NIS expression combined with Na131I/5‑FC on human thyroid cancer

Authors:
- Meng‑Hui Yuan
- Long‑Xiao Wei
- Run‑Suo Zhou
- Hai‑Feng Xu
- Jun‑Yan Wang
- Qian‑Rong Bai
View Affiliations

Affiliations: Department of Nuclear Medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: October 12, 2017 https://doi.org/10.3892/ol.2017.7175
Pages: 7431-7436

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer is the most common type of malignant endocrine tumor diagnosed. Previous studies have indicated that gene therapy is the most promising and effective therapeutic method for thyroid cancer. Therefore, in the present study, Na131I/5‑fluorocytosine (5‑FC) treatment was combined with cytosine deaminase (CD, encoded by the CDA gene) and sodium iodide symporter (NIS, encoded by the SLC5A5 gene) to act together as a therapeutic tool for thyroid cancer. The present study explored the combined cytotoxic effects of adenovirus‑mediated CD and NIS under the control of the progression elevated gene‑3 (PEG‑3) promoter (Ad‑PEG‑3‑CD‑NIS) with Na131I/5‑FC against the human thyroid cancer TT cell line in vitro. The PEG‑3 fragment was obtained by polymerase chain reaction (PCR) using rat genomic DNA as the template, and then Ad‑PEG‑3‑CDA‑SLC5A5 was constructed using XbaI. TT cells were transfected by recombinant adenovirus. The method of reverse transcription‑quantitative PCR was performed to test the expression of CD and NIS at the level of transcription. The morphological change was assessed by fluorescence microscopy and investigated by western blot analysis. An MTT assay was used to determine the number of living cells inhibited by single or combination therapies on TT cells. The results indicated that the PEG‑3 was successfully cloned, and was also positively regulated in 293 cells. CDA and SLC5A5 genes were highly expressed in TT cells. Na131I combined with 5‑FC significantly decreased the human thyroid cancer cells. In conclusion, combination therapy of Ad‑PEG3‑CDA‑SLC5A5 and Na131I/5‑FC induces significantly more apoptotic characteristics than either single treatment with Ad‑PEG‑3‑CDA‑SLC5A5 or Na131I/5‑FC, and low doses of Ad‑PEG‑3‑CDA‑SLC5A5 enhanced the cytotoxic effects.

View Figures

View References

1	Wartofsky L: Increasing world incidence of thyroid cancer: Increased detection or higher radiation exposure? Hormones (Athens). 9:103–108. 2010. View Article : Google Scholar : PubMed/NCBI
2	Wang C, Lu S, Jiang J, Jia X, Dong X and Bu P: Has-microRNA-101 suppresses and invasion by targeting Rac1 in thyroid cancer cells. Oncol Lett. 8:1815–1821. 2014.PubMed/NCBI
3	Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
4	Romagnoli S, Moretti S, Voce P and Puxeddu E: Targeted molecular therapies in thyroid carcinoma. Arq Bras Endocrinol Metab. 53:1361–1073. 2009. View Article : Google Scholar
5	Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C and Wong RJ: Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One. 7:e467262012. View Article : Google Scholar : PubMed/NCBI
6	Gild ML, Bullock M, Robinson BG and Clifton-Bligh R: Multikinase inhibitors: A new option for the treatment of thyroid cancer. Nat Rev Endocrinol. 7:617–624. 2011. View Article : Google Scholar : PubMed/NCBI
7	Khan MS, Pandith AA, Hussain M, Iqbal M, Khan NP, Wani KA, Masoodi SR and Mudassar S: Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS T81C single nucleotide polymorphism (case-control study). Tumor Biol. 34:521–529. 2013. View Article : Google Scholar
8	Yazawa K, Fisher WE and Brunicardi FC: Current Progress in Suicide Gene Therapy for Cancer. World J Surg. 26:783–789. 2002. View Article : Google Scholar : PubMed/NCBI
9	Springer CJ and Niculescu-Duvaz I: Prodrug-activating systems in suicide gene therapy. J Clin Invest. 105:1161–1167. 2010. View Article : Google Scholar
10	Wang Z, Wang B, Guo H, Shi G and Hong X: Clinicopathological significance and potential drug target of T-cadherin in NSCLC. Drug Des Devel Ther. 9:207–316. 2014.PubMed/NCBI
11	Chung JK: Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med. 43:1188–1200. 2002.PubMed/NCBI
12	Guerrieri F, Piconese S, Lacoste C, Schinzari V, Testoni B, Valogne Y, Gerbal-Chaloin S, Samuel D, Bréchot C, Faivre J and Levrero M: The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells. Cell Death Dis. 4:e8072013. View Article : Google Scholar : PubMed/NCBI
13	McCormick F: Cancer gene therapy: Fringe or cutting edge? Nat Rev Cancer. 1:130–141. 2001. View Article : Google Scholar : PubMed/NCBI
14	Breyer B, Jiang W, Cheng HW, Zhou L, Paul R, Feng T and He TC: Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther. 1:49–162. 2001. View Article : Google Scholar
15	Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E and Devesa SS: Follicular thyroid cancer indicence patterns in the Unites States, 1980–2009. Thyroid. 23:1015–1021. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S and Schlumberger M: Expression of the Na+/I- symporter gene in human thyroid tumors: A comparison study with other thyroid-specific genes. J Clin Endocrinol Metal. 84:3228–3234. 1999. View Article : Google Scholar
17	Zhu Y, Cheng M, Yang Z, Zeng CY, Chen J, Xie Y, Luo SW, Zhang KH, Zhou SF and Lu NH: Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts. Drug Des Devel Ther. 8:2449–2462. 2014. View Article : Google Scholar : PubMed/NCBI
18	Xie L, Semenciw R and Mery L: Cancer incidence in Canada: Trends and projections (1983–2032). Health Promot Chronic Dis Prev Can. 35 Suppl 1:S2–S186. 2015.(In English, French). View Article : Google Scholar
19	Maxwell JE, Sherman SK, O'Dorision TM and Howe JR: Medical management of metastatic medullary thyroid cancer. Cancer. 120:3287–3301. 2014. View Article : Google Scholar : PubMed/NCBI
20	National Cancer Institute, . SEER stat fact sheets: Thyroid cancer. http://seer.cancer.gov/statfacts/html/thyro.htmlJanuary 12–2015
21	Yip L: Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol. 111:43–50. 2015. View Article : Google Scholar : PubMed/NCBI
22	Chai LP, Wang ZF, Liang WY, Chen L, Chen D, Wang AX and Zhang ZQ: In vitro and in vivo effect of 5-FC gene therapy with TNF and CD suicide gene on human laryngeal carcinoma cell line Hep-2. PLoS One. 8:e611362013. View Article : Google Scholar : PubMed/NCBI
23	Kogai T and Brent GA: The sodium iodide symporter (NIS): Regulation and approaches to targeting for cancer therapeutics. Phamacol Ther. 135:355–370. 2012. View Article : Google Scholar
24	Bentires-Alj M, Hellin AC, Lechanteur C, Princen F, Lopez M, Fillet G, Gielen J, Merville MP and Bours V: Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther. 7:20–26. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kucerova L, Skolekova S, Demkova L, Bohovic R and Matuskova M: Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC/5-FC therapy in human melanoma xenograft model. Gene Ther. 21:874–887. 2014. View Article : Google Scholar : PubMed/NCBI
26	Zimmer AM, Kazikiewicz JK, Rosen ST and Spies SM: Chromatographic evaluation of the radiochemical purity of Na131I: Effect on monoclonal antibody labeling. Int J Rad Appl Instrum B. 14:533–534. 1987. View Article : Google Scholar : PubMed/NCBI
27	Su ZZ, Shi Y and Fisher PB: Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. Proc Natl Acad Sci USA. 94:pp. 9125–9130. 1997, View Article : Google Scholar : PubMed/NCBI
28	Su ZZ, Goldstein NI, Jiang H, Wang MN, Duigou GJ, Young CS and Fisher PB: PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis. Proc Natl Acad Sci USA. 96:pp. 15115–15120. 1999, View Article : Google Scholar : PubMed/NCBI
29	Goers L, Freemont P and Polizzi KM: Co-culture systems and technologies: Taking synthetic biology to the next level. J R Soc Interface. 11:201400652014. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Pacholska A, Wirth T, Samaranayake H, Pikarainen J, Ahmad F and Ylä-Herttuala S: Increased invasion of malignant gliomas after 15-LO-1 and HSV-tk/ganciclovir combination gene therapy. Cancer Gene Ther. 19:870–874. 2012. View Article : Google Scholar : PubMed/NCBI
32	Hsiao HT, Xing L, Deng X, Sun X, Ling CC and Li GC: Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells. Oncol Rep. 32:723–729. 2014. View Article : Google Scholar : PubMed/NCBI
33	Li C, Penet MF, Wildes F, Takagi T, Chen Z, Winnard PT, Artemov D and Bhujwalla ZM: Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano. 4:6707–6716. 2010. View Article : Google Scholar : PubMed/NCBI
34	Watanabe M, Nasu Y and Kumon H: Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review). Oncol Lett. 7:595–601. 2014.PubMed/NCBI